Illumina
ILMN
$278.17
+5.14%
Illumina Inc. is a life sciences tools company that develops and manufactures DNA sequencing instruments, consumables, and related services, generating over 90% of its revenue from sequencing platforms used in research, clinical diagnostics, and applied markets, alongside a smaller microarray franchise. As the dominant incumbent in next-generation sequencing with an installed base that creates a powerful razor-and-blade consumables annuity, Illumina occupies a near-monopoly position in high-throughput genomic analysis, though it faces intensifying competition in long-read and lower-throughput segments. The current investor narrative has shifted decisively from a multi-year turnaround and restructuring story to a growth re-acceleration thesis, with the stock up roughly 175% over the past year as revenue growth returned to high-single digits and management raised guidance. Debate now centers on whether the sharp re-rating is justified by durable clinical sequencing demand and margin recovery, or whether the stock has run ahead of fundamentals after its massive move, with some sell-side commentary explicitly cautioning investors to wait for a pullback.…
ILMN
Illumina
$278.17
Related headlines
Investment Opinion: Should I buy ILMN Today?
The synthesized recommendation is Hold, with a cautious bias. While Illumina's fundamental story is improving—revenue growth of 9.65% YoY, a 66.44% gross margin, and a 'buy' consensus rating—the stock's 175% one-year rally has pushed it 27% above the average analyst target of $214.60, creating a significant valuation disconnect. The risk/reward is skewed to the downside in the near term, and investors would be better served waiting for a pullback toward the $200-$215 support zone before adding exposure.
The supporting evidence for a Hold is mixed but leans cautious. On the positive side, revenue has re-accelerated to 9.65% YoY in Q2 2026, gross margins have stabilized above 66%, and TTM free cash flow of $939 million comfortably funds buybacks. The trailing PE of 24.54x is not extreme relative to history, and the EV/EBITDA of 15.09x is moderate. However, the forward PE of 44.70x implies an earnings decline, and the PS ratio of 4.81x is at the low end of its historical range but still above sector peers. The stock's 27% premium to the average analyst target is a red flag, suggesting limited upside unless analysts revise targets upward.
The biggest risks that could invalidate the Hold thesis are a sharp revenue deceleration, margin compression, and multiple contraction. If revenue growth falls below 5% or gross margins drop below 65%, the stock could correct toward the $200 level. Conversely, if Q3 earnings beat and management raises guidance again, the stock could break above $280 and head toward the high target of $305. The valuation verdict is that Illumina is fairly valued to slightly overvalued relative to its own history and peers, with the market pricing in a full recovery. A pullback to the $200-$215 range would make the risk/reward more attractive.
Sign up to view all
ILMN 12-Month Price Forecast
Illumina's fundamental turnaround is real, with revenue growth re-accelerating to 9.65% YoY and margins stabilizing above 66%. However, the stock's 175% one-year rally has pushed it 27% above the average analyst target, and the forward PE of 44.70x suggests the market is pricing in a sharp earnings decline. The risk/reward is balanced but skewed to the downside in the near term, as the stock is technically overextended and vulnerable to a mean-reversion pullback. I would upgrade to bullish if the stock pulls back to the $200-$215 support zone and revenue growth accelerates above 10%, or downgrade to bearish if revenue growth decelerates below 5% or gross margins fall below 65%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Illumina's 12-month outlook, with a consensus price target around $233.55 and implied upside of -16.0% versus the current price.
Average Target
$233.55
0 analysts
Implied Upside
-16.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$113 - $365
Analyst target range
Coverage is solid with 20 analysts, and the consensus recommendation is "buy" with a recommendation mean of 2.43 (where lower is more bullish), indicating a moderately bullish but not euphoric stance. The average price target is $214.60, which against the current price of $273.04 implies roughly -21.4% downside — a notable disconnect where the stock has blown past the consensus target, suggesting analysts have been slow to revise upward or that the market is ahead of the sell-side. Estimated EPS averages $8.95 for the forward period, and estimated revenue averages $6.00 billion, framing the fundamental expectations underpinning targets.
The target range is extremely wide, from a low of $113.00 to a high of $305.00 — a spread of $192, or roughly 70% of the current price — signaling very high uncertainty and low conviction among analysts. The high target of $305 assumes continued multiple expansion and accelerating clinical sequencing adoption, while the low target of $113 prices in margin compression and competitive share loss. Recent institutional actions skew positive, with UBS upgrading to Buy from Neutral on September 9, 2026, and Piper Sandler, Leerink, RBC, Stifel, and JP Morgan all maintaining bullish ratings through late September, though Citigroup remains a Sell and Canaccord a Hold, indicating the bull-bear debate is very much alive. The fact that the stock trades 27% above the average target is a caution flag: either analysts will chase the price higher with upgrades, or the stock is vulnerable to a sharp correction if it reverts toward consensus.
Bulls vs Bears: ILMN Investment Factors
The bull case rests on Illumina's re-accelerating revenue growth (9.65% YoY), high-margin consumables annuity (66.44% gross margin), and strong cash generation ($939 million TTM FCF), supported by a dominant sequencing monopoly and a 'buy' consensus rating. However, the bear case is equally compelling: the stock trades 27% above the average analyst target, the forward PE of 44.70x implies an earnings decline, and the 175% one-year rally has left it technically overextended at 97.5% of its 52-week range. Currently, the bear evidence appears stronger on a near-term basis due to the extreme valuation disconnect and overbought technicals, but the bull case has merit if growth accelerates further. The single most important tension is whether the market's aggressive re-rating is justified by durable clinical sequencing demand and margin recovery, or whether it has simply run ahead of fundamentals—a resolution that will likely hinge on upcoming earnings and guidance.
Bullish
- Revenue re-acceleration to 9.65% YoY: Q2 2026 revenue of $1.159 billion grew 9.65% year-over-year, up from $1.057 billion in Q2 2025, marking a clear return to consistent mid-to-high single-digit growth after a period of stagnation. The sequential progression from $1.041 billion in Q1 2025 to $1.159 billion in Q2 2026 shows a business that has stabilized and is now expanding.
- High-margin razor-and-blade model: Gross margin of 66.44% in Q2 2026, up from 65.80% in Q1 2025, reflects the powerful consumables annuity from Illumina's installed base of sequencing instruments. With 91% of revenue from sequencing ($1.054 billion of $1.159 billion), the recurring consumables stream provides high visibility and pricing power.
- Strong profitability and cash generation: Q2 2026 net income of $207 million (17.86% net margin) and EBITDA of $330 million (28.47% EBITDA margin) demonstrate robust operating leverage. Trailing-twelve-month free cash flow of $939 million comfortably funds $242 million in quarterly buybacks, enhancing per-share value.
- Analyst consensus remains bullish: With 20 analysts covering the stock, the consensus recommendation is 'buy' (mean 2.43), and recent institutional actions skew positive, including UBS upgrading to Buy on September 9, 2026, and Piper Sandler, Leerink, RBC, Stifel, and JP Morgan maintaining bullish ratings. The high target of $305 implies 11.7% upside from the current price.
Bearish
- Stock trades 27% above average analyst target: The current price of $273.04 is 27.2% above the consensus average target of $214.60, a rare disconnect that suggests the stock has run ahead of sell-side expectations. Either analysts will chase with upgrades, or the stock is vulnerable to a sharp correction toward consensus.
- Forward PE of 44.70x implies earnings decline: The forward PE of 44.70x is nearly double the trailing PE of 24.54x, implying the market expects a significant earnings decline next year. This unusual gap is partly due to a one-time $705 million net income in Q3 2024, but it also signals that current earnings may not be sustainable.
- Extreme technical overextension: The stock is up 174.96% over the past year and 103.23% year-to-date, trading at 97.5% of its 52-week range ($88.00 low, $280.17 high). With a 1-month gain of 28.04% and a beta of 1.467, the shares are highly volatile and prone to a sharp mean-reversion pullback.
- Wide analyst target range signals uncertainty: The target range spans from $113 to $305, a $192 spread (70% of the current price), indicating very low conviction among analysts. The low target of $113 prices in margin compression and competitive share loss, representing 58.6% downside from the current price.
ILMN Technical Analysis
Illumina is in a powerful, sustained uptrend, with the stock up 174.96% over the past year and 103.23% year-to-date, dramatically outpacing the S&P 500's 15.01% and 12.86% respective gains. At a current price of $273.04, the shares are trading at approximately 97.5% of their 52-week range (52-week low of $88.00, high of $280.17), positioning them just below all-time-range highs and signaling strong momentum but also meaningful overextension risk. This near-high positioning means buyers are paying up for a stock that has already priced in substantial good news, leaving limited margin of safety if the growth narrative wobbles.
Short-term momentum is accelerating aggressively, with a 1-month gain of 28.04% and a 3-month gain of 44.71%, both far exceeding the 6-month gain of 114.35% on an annualized basis and confirming that the pace of appreciation has intensified in recent weeks. Relative strength versus SPY is extraordinary across every window — 27.45% over 1 month, 41.37% over 3 months, and 159.95% over 1 year — indicating persistent, broad-based outperformance rather than a single spike. The 1-month trend is fully aligned with, not diverging from, the longer-term uptrend, which argues against a trend reversal but does raise the probability of a sharp mean-reversion pullback given the parabolic recent slope.
Key technical support sits at the 52-week low of $88.00, though far more relevant near-term support likely lies around the $200-$215 zone where the stock consolidated in August, while resistance is defined by the 52-week high of $280.17. A clean breakout above $280 would signal continuation of the momentum regime and likely invite trend-following capital, whereas a breakdown below $200 would mark a significant trend violation and could trigger a deeper correction. With a beta of 1.467, Illumina is roughly 47% more volatile than the broad market, meaning position sizing should be scaled down accordingly, and the 25.66% max drawdown underscores that this name can shed a quarter of its value even within a broader uptrend.
Beta
1.42
1.42x market volatility
Max Drawdown
-25.7%
Largest decline past year
52-Week Range
$88-$309
Price range past year
Annual Return
+188.4%
Cumulative gain past year
| Period | ILMN Return | S&P 500 |
|---|---|---|
| 1m | +35.7% | +2.1% |
| 3m | +46.3% | +3.1% |
| 6m | +130.0% | +14.6% |
| 1y | +188.4% | +16.0% |
| ytd | +107.0% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ILMN Fundamental Analysis
Illumina's revenue trajectory has re-accelerated, with Q2 2026 revenue of $1.159 billion growing 9.65% year-over-year, up from $1.091 billion in Q1 2026 and $1.057 billion in Q2 2025. The sequential progression from $1.041 billion (Q1 2025) to $1.083 billion (Q3 2025) to $1.160 billion (Q4 2025) and now $1.159 billion (Q2 2026) shows a business that has stabilized and returned to consistent mid-to-high single-digit growth. Sequencing dominates the mix at $1.054 billion versus just $105 million from microarrays, meaning the entire growth story hinges on sequencing instrument and consumables demand — a concentrated but high-moat revenue base.
Profitability is robust and improving, with Q2 2026 net income of $207 million on a 17.86% net margin and a gross margin of 66.44%, up modestly from 66.09% in Q1 2026 and 65.80% in Q1 2025. Operating income of $245 million equates to a 21.14% operating margin, and EBITDA of $330 million represents a 28.47% EBITDA margin, both healthy for a life sciences tools company. The trend in gross margin from 65.80% (Q1 2025) to 67.07% (Q4 2025) to 66.44% (Q2 2026) suggests margins have stabilized at a high level rather than compressing, supporting the earnings recovery thesis.
Balance sheet health is solid but not pristine: debt-to-equity stands at 0.94, the current ratio is 2.08, and cash on hand was $1.04 billion at the end of Q2 2026. Free cash flow on a trailing-twelve-month basis is $939 million, and quarterly free cash flow has ranged from $161 million to $267 million over the past four quarters, comfortably funding operations and buybacks (including $242 million repurchased in Q2 2026). Return on equity is an impressive 31.22%, though the 0.94 debt-to-equity ratio and $939 million TTM FCF against a $20.8 billion market cap imply a modest FCF yield of roughly 4.5%, meaning the company generates real cash but is not a deep-value cash machine at current prices.
Quarterly Revenue
$1.2B
2026-06
Revenue YoY Growth
+9.7%
YoY Comparison
Gross Margin
66.4%
Latest Quarter
Free Cash Flow
$939000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ILMN Overvalued?
Because Illumina is profitable with positive trailing net income, the PE ratio is the appropriate primary metric; the stock trades at a trailing PE of 24.54x and a forward PE of 44.70x. The unusual gap — forward PE nearly double the trailing PE — implies the market expects earnings to decline meaningfully next year, or that trailing earnings are inflated by one-time items, which is a critical caveat given the Q3 2024 quarter included a $705 million net income figure driven by a large one-time gain. The PEG ratio of -0.14 is not meaningful given negative or distorted growth inputs, and the PS ratio of 4.81x and EV/Sales of 9.23x provide cleaner cross-checks.
Against the broader Medical-Diagnostics & Research sector, Illumina's 4.81x PS and 9.23x EV/Sales look elevated relative to typical tools-and-diagnostics peers trading in the 3-6x sales range, implying a premium that is partly justified by its sequencing monopoly but also reflects the market pricing in a full recovery. The 15.09x EV/EBITDA is more moderate and suggests that on a cash-earnings basis the valuation is less stretched than the headline PE implies. The 7.65x price-to-book ratio is rich versus a sector where 3-5x is more common, reflecting the asset-light, high-ROIC nature of the franchise but also leaving little room for execution missteps.
Historically, Illumina's PS ratio has ranged from roughly 12x to 50x over the past several years, and the current 4.81x PS is actually near the low end of that historical band — a striking observation given the stock's 175% one-year gain, and one explained by the fact that revenue and earnings have grown into the multiple. The trailing PE of 24.54x compares favorably to historical peaks above 100x and troughs in negative territory, suggesting that on an earnings basis the stock is not at a historical extreme. The key risk is that the forward PE of 44.70x implies the market is pricing in a sharp earnings decline, so if that decline does not materialize, the stock could re-rate higher; if it does, the current price embeds disappointment.
PE
24.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~130x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.1x
Enterprise Value Multiple
Investment Risk Disclosure
Illumina faces financial risks stemming from its moderate debt burden and reliance on continued growth to justify its valuation. The debt-to-equity ratio of 0.94 is manageable but not insignificant, and with a current ratio of 2.08, liquidity is adequate. However, the forward PE of 44.70x implies the market expects a sharp earnings decline, and if that decline materializes, the stock could de-rate significantly. Additionally, the company's revenue is highly concentrated in sequencing (91% of total), making it vulnerable to competitive disruptions or pricing pressure in that segment. Free cash flow of $939 million TTM provides a cushion, but the FCF yield of roughly 4.5% is modest and offers little margin of safety if growth stalls.
Market and competitive risks are pronounced given Illumina's premium valuation and high beta. The stock trades at 4.81x sales and 9.23x EV/Sales, well above the 3-6x range typical for diagnostics peers, leaving it exposed to multiple compression if growth disappoints. With a beta of 1.467, Illumina is 47% more volatile than the market, amplifying downside during sector rotations. Recent news highlights the risk of a pullback: a Zacks article on August 28, 2026, noted that while fundamentals are strong, the massive run-up suggests investors should wait for a pullback. Competition in long-read and lower-throughput sequencing segments is intensifying, threatening Illumina's market share.
In a worst-case scenario, a combination of slowing revenue growth, margin compression, and multiple contraction could drive the stock sharply lower. The 52-week low of $88.00 represents a 67.8% decline from the current price of $273.04, and the analyst low target of $113 implies 58.6% downside. A realistic adverse scenario might involve revenue growth decelerating to low single digits, gross margins falling below 60%, and the PS ratio compressing to 3x, which could push the stock toward the $120-$150 range. From the current price, that would represent a loss of 45-56%. The max drawdown of 25.66% over the past year shows that even within an uptrend, significant corrections are possible.
FAQ
The most severe risk is valuation compression: the stock trades at a premium to peers and 27% above the average analyst target, so any growth disappointment could trigger a sharp correction. Financial risks include a debt-to-equity ratio of 0.94 and a forward PE of 44.70x that implies an earnings decline, which could pressure the stock if it materializes. Competitive risks are rising in long-read and lower-throughput sequencing, threatening Illumina's market share. Macro risks are amplified by a beta of 1.467, making the stock 47% more volatile than the market. Finally, company-specific risk includes revenue concentration in sequencing (91% of total), leaving it vulnerable to a slowdown in that segment.
Our 12-month forecast has three scenarios: a base case (50% probability) with a target range of $215-$250, assuming revenue growth stabilizes at 8-10% and the stock consolidates; a bull case (25% probability) targeting $305-$330, driven by accelerating growth and multiple expansion; and a bear case (25% probability) targeting $113-$150, assuming revenue deceleration and margin compression. The most likely scenario is the base case, where the stock digests its massive run-up and trades toward the average analyst target of $214.60. The key assumption is that revenue growth remains in the high single digits and gross margins hold above 66%.
ILMN appears overvalued on most metrics. Its PS ratio of 4.81x and EV/Sales of 9.23x are above the 3-6x range typical for diagnostics peers, and the price-to-book of 7.65x is rich versus the sector's 3-5x. The trailing PE of 24.54x is not extreme, but the forward PE of 44.70x implies a sharp earnings decline, suggesting the market is pricing in a full recovery. The stock trades 27% above the average analyst target of $214.60, a rare disconnect. While the PS ratio is at the low end of its historical range (12x-50x), the current valuation leaves little room for error.
At the current price of $273.04, ILMN is not an attractive buy due to its 27% premium to the average analyst target of $214.60 and its forward PE of 44.70x, which implies an earnings decline. The stock has rallied 175% over the past year and trades at 97.5% of its 52-week range, leaving limited margin of safety. However, the company's fundamentals are improving, with revenue growth of 9.65% YoY and a 66.44% gross margin. For long-term investors, a pullback to the $200-$215 support zone would present a better entry point. The risk/reward is currently skewed to the downside, so waiting for a correction is prudent.
ILMN is better suited for long-term investors who can tolerate volatility, given its beta of 1.467 and 25.66% max drawdown over the past year. The company has a strong competitive moat in sequencing, generates $939 million in TTM free cash flow, and pays no dividend, so returns depend on capital appreciation. Short-term trading is risky due to the stock's overextended technicals and 27% premium to analyst targets. A suggested minimum holding period is 2-3 years to allow for the clinical sequencing market to mature and for margin expansion to play out. Investors should be prepared for significant drawdowns along the way.